| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | -36 | -36 |
| Net change in cash and cash equivalents and restricted cash | 11,205 | 1,183 |
| Cash and cash equivalents at beginning of period | 35,859 | - |
| Cash and cash equivalents at end of period | 47,064 | - |
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)